Biggest change(Dollars in thousands) Twelve months ended December 31: 2022 2021 Net income $ 15,211 $ 26,255 Depreciation 10,454 10,452 Non-cash stock-based compensation 46 - Interest and dividend income (4,870 ) (3,119 ) Non-cash interest expense and amortization of deferred financing costs 128 127 Loss on disposal of property and equipment 64 11 Loss on derivative instruments 24,360 10,377 Loss on marketable securities 8,546 70 Income tax benefit (1,473 ) (10,325 ) Adjusted EBITDA $ 52,466 $ 33,848 The following table reconciles adjusted EBITDA with cash flows from operations, the most directly comparable GAAP liquidity financial measure: (Dollars in thousands) Twelve months ended December 31: 2022 2021 Net cash provided by operating activities $ 52,451 $ 44,084 Benefit for deferred income taxes 1,822 10,454 Interest and dividend income (4,870 ) (3,119 ) Income tax benefit (1,473 ) (10,325 ) Loss on derivative instruments 24,360 10,377 Change in fair value of derivative instruments 343 (609 ) Changes in operating assets and liabilities, net (20,168 ) (15,699 ) Other non-operating income 1 - Impairment of intangible asset - (1,315 ) Adjusted EBITDA $ 52,466 $ 33,848 36 Table of Contents Results of Operations Consolidated 2022 Compared to 2021: 2021 Compared to 2020: Change Change (Dollars in thousands) 2022 2021 $ % 2021 2020 $ % Sales $ 396,014 $ 321,386 $ 74,628 23.2 % $ 321,386 $ 204,505 $ 116,881 57.2 % Volume/product mix effect $ (30,301 ) (9.4 %) $ (21,288 ) (10.4 %) Price effect $ 104,929 32.6 % $ 138,169 67.6 % Gross profit $ 28,993 $ 23,537 $ 5,456 23.2 % $ 23,537 $ 31,307 $ (7,770 ) (24.8 %) Operating expense $ 11,447 $ 10,639 $ 808 7.6 % $ 10,639 $ 8,968 $ 1,671 18.6 % Other expense (income) $ 3,808 $ (3,032 ) $ 6,840 NA $ (3,032 ) $ (9,439 ) $ 6,407 (67.9 %) Pretax income $ 13,738 $ 15,930 $ (2,192 ) (13.8 %) $ 15,930 $ 31,778 $ (15,848 ) (49.9 %) Income tax benefit $ (1,473 ) $ (10,325 ) $ 8,852 (85.7 %) $ (10,325 ) $ (14,786 ) $ 4,461 (30.2 %) Net income $ 15,211 $ 26,255 $ (11,044 ) (42.1 %) $ 26,255 $ 46,564 $ (20,309 ) (43.6 %) 2022 Compared to 2021 Consolidated sales revenue increased 23.2% or $74,628 in 2022 compared to 2021 primarily from higher average sales prices in the biofuel segment and, to a lesser extent, in the chemical segment.
Biggest changeRealized gains and losses are included in Adjusted EBITDA in both 2022 and 2023. 36 Table of Contents Results of Operations Consolidated 2023 Compared to 2022: 2022 Compared to 2021: Change Change (Dollars in thousands) 2023 2022 $% 2022 2021 $% Sales $ 368,250 $ 396,014 $ (27,764 ) (7.0 )% $ 396,014 $ 321,386 $ 74,628 23.2 % Volume/product mix effect $ 45,350 11.5 % $ (30,301 ) (9.4 )% Price effect $ (73,114 ) (18.5 )% $ 104,929 32.6 % Gross profit $ 40,979 $ 28,993 $ 11,986 41.3 % $ 28,993 $ 23,537 $ 5,456 23.2 % Operating expense $ 13,611 $ 11,447 $ 2,164 18.9 % $ 11,447 $ 10,639 $ 808 7.6 % Other (income) expense $ (10,015 ) $ 3,808 $ (13,823 ) NA $ 3,808 $ (3,032 ) $ 6,840 NA Pretax income $ 37,383 $ 13,738 $ 23,645 172.1 % $ 13,738 $ 15,930 $ (2,192 ) (13.8 )% Income tax provision (benefit) $ 1 $ (1,473 ) $ 1,474 NA $ (1,473 ) $ (10,325 ) $ 8,852 (85.7 )% Net income $ 37,382 $ 15,211 $ 22,171 145.8 % $ 15,211 $ 26,255 $ (11,044 ) (42.1 )% 2023 Compared to 2022 Consolidated sales revenue decreased 7.0% or $27,764 in 2023 compared to 2022 primarily from lower average sales prices in the biofuel segment ($71,198) and, to a lesser extent, in the chemical segment ($1,916).
No assurances can be given that we will continue to sell to such major refiners, or, if we do sell, the volume we will sell or the profit margin we will realize.
No assurances can be given that we will continue to sell to such major refiners, or, if we do sell, the volume we will sell or the profit margin we will realize.
We do not believe that the loss of this customer would have a material adverse effect on our biofuels segment or on us as a whole in that: (i) unlike our custom manufacturing products, biodiesel is a commodity with a large potential customer base; (ii) we believe that we could readily sell our biodiesel to other customers as potential demand from other customers for biodiesel exceeds our production capacity; (iii) our sales to this customer are not under fixed terms and the customer has no fixed obligation to purchase any minimum quantities except as stipulated by short term purchase orders; and (iv) the prices we receive from this customer are based upon then-market rates, as would be the case with sales of this commodity to other customers.
We do not believe that the loss of this customer would have a material adverse effect on our biofuels segment or on us as a whole in that: (i) unlike our custom manufacturing products, biodiesel is a commodity with a large potential customer base; (ii) we believe that we could readily sell our biodiesel to other customers as potential demand from other customers for biodiesel exceeds our production capacity; (iii) our sales to this customer are not under fixed terms and the customer has no fixed obligation to purchase any minimum quantities except as stipulated by short term purchase orders; and (iv) the prices we receive from this customer are based upon then-market rates, as would be the case with sales of this commodity to other customers.
Consolidated Leverage Ratio Adjusted SOFR Rate Loans and Letter of Credit Fee Base Rate Loans Commitment Fee 1.00% 0.00% 0.15% ≥ 1.00:1.0 And 1.25% 0.25% 0.15% ≥ 1.50:1.0 And 1.50% 0.50% 0.20% ≥ 2.00:1.0 And 1.75% 0.75% 0.20% ≥ 2.50:1.0 2.00% 1.00% 0.25% Certain of our subsidiaries have entered into guarantees of payment on behalf of the Company for amounts outstanding under the Credit Facility.
Adjusted SOFR Rate Loans Consolidated Leverage Ratio and Letter of Credit Fee Base Rate Loans Commitment Fee 1.00 % 0.00 % 0.15 % ≥ 1.00:1.0 And 1.25 % 0.25 % 0.15 % ≥ 1.50:1.0 And 1.50 % 0.50 % 0.20 % ≥ 2.00:1.0 And 1.75 % 0.75 % 0.20 % ≥ 2.50:1.0 2.00 % 1.00 % 0.25 % Certain of our subsidiaries have entered into guarantees of payment on behalf of the Company for amounts outstanding under the Credit Facility.
In particular, our management believes that adjusted EBITDA permits a comparative assessment of our operating performance and liquidity, relative to a performance and liquidity based on GAAP results, while isolating the effects of depreciation and amortization, which may vary among our operating segments without any correlation to their underlying operating performance, and of non-cash stock-based compensation expense, which is a non-cash expense that varies widely among similar companies, and gains and losses on derivative instruments, which can cause net income to appear volatile from period to period relative to the sale of the underlying physical product.
In particular, our management believes that adjusted EBITDA permits a comparative assessment of our operating performance and liquidity, relative to a performance and liquidity based on GAAP results, while isolating the effects of depreciation and amortization, which may vary among our operating segments without any correlation to their underlying operating performance, and of non-cash stock-based compensation expense, which is a non-cash expense that varies widely among similar companies, and unrealized gains and losses on derivative instruments, which can cause net income to appear volatile from period to period relative to the sale of the underlying physical product.
SSIPA/LiSIPA revenues are generated from a diverse customer base of nylon fiber manufacturers and other customers that produce condensation polymers. Contract sales are, in certain instances, indexed to key raw materials for inflation; otherwise, there is no pricing mechanism or specific protection against raw material or conversion cost changes.
SSIPA/LiSIPA revenues are generated from a diverse customer base of nylon and polyester fiber manufacturers and other customers that produce condensation polymers. Contract sales are, in certain instances, indexed to key raw materials for inflation; otherwise, there is no pricing mechanism or specific protection against raw material or conversion cost changes.
We define adjusted EBITDA as net income before interest, income taxes, depreciation, and amortization expenses, excluding, when applicable, non-cash stock-based compensation expenses, public offering expenses, acquisition-related transaction costs, purchase accounting adjustments, losses on disposal of property and equipment, gains or losses on derivative instruments, and other non-operating income or expenses.
We define adjusted EBITDA as net income before interest, income taxes, depreciation, and amortization expenses, excluding, when applicable, non-cash stock-based compensation expenses, public offering expenses, acquisition-related transaction costs, purchase accounting adjustments, losses on disposal of property and equipment, unrealized gains or losses on derivative instruments, and other non-operating income or expenses.
Some, but not all, of these products have pricing mechanisms and/or protections against raw material or conversion cost changes. Performance chemicals consist of specialty chemicals that are manufactured to general market-determined specifications and are sold to a broad customer base.
Some, but not all, of these products have pricing mechanisms and/or protections against raw material, energy, or conversion cost changes. Performance chemicals consist of specialty chemicals that are manufactured to general market-determined specifications and are sold to a broad customer base.
Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. The provision for (benefit from) income taxes represents income taxes paid or payable for the current year plus the change in deferred taxes during the year.
Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. The provision for (benefit from) income taxes represent income taxes paid or payable for the current year plus the change in deferred taxes during the year.
Historically, we finance capital requirements for our business with cash flows from operations and have not had the need to incur bank indebtedness to finance any of our operations during the periods discussed herein. 43 Table of Contents Credit Facility On March 30, 2020, the Company, with FutureFuel Chemical Company as the borrower and certain of the Company’s other subsidiaries as guarantors, amended and restated its credit agreement (the “Credit Agreement”) originally entered into on April 16, 2015 (as amended, the “Prior Credit Agreement”) with the lenders party thereto, Regions Bank as administrative agent and collateral agent, and PNC Bank, N.A., as syndication agent.
Historically, we finance capital requirements for our business with cash flows from operations and have not had the need to incur bank indebtedness to finance any of our operations during the periods discussed herein. 42 Table of Contents Credit Facility On March 30, 2020, the Company, with FutureFuel Chemical Company as the borrower and certain of the Company’s other subsidiaries as guarantors, amended and restated its credit agreement (the “Credit Agreement”) originally entered into on April 16, 2015 (as amended, the “Prior Credit Agreement”) with the lenders party thereto, Regions Bank as administrative agent and collateral agent, and PNC Bank, N.A., as syndication agent.
Performance chemicals revenue (comprised of multi-customer products which are sold based on specification) was $22,156 in 2022, an increase of 31.4% or $5,289 from 2021. This increase resulted from higher selling prices of our glycerin products partially offset by lower volumes of polymer modifiers. Gross profit for the chemicals segment increased 83.6% or $11,675 in 2022 compared with 2021.
Performance chemicals revenue (comprised of multi-customer products which were sold based on specification) was $22,156 in 2022, an increase of 31.4% or $5,289 from 2021. This increase resulted from higher selling prices of our glycerin products partially offset by lower volumes of polymer modifiers. Gross profit for the chemicals segment increased 83.6% or $11,675 in 2022 compared with 2021.
Depreciation is provided for using the straight-line method over the associated asset’s estimated useful lives. 41 Table of Contents Revenue Recognition We recognize revenue in accordance with Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers , when performance obligations of the customer contract are satisfied. We sell to customers through master sales agreements or standalone purchase orders.
Depreciation is provided for using the straight-line method over the associated asset’s estimated useful lives. 40 Table of Contents Revenue Recognition We recognize revenue in accordance with Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers , when performance obligations of the customer contract are satisfied. We sell to customers through master sales agreements or standalone purchase orders.
Income tax benefit The income tax benefit in 2022 was $1,473 or an effective tax rate of (10.7%) as compared to a benefit in 2021 of $10,325 or an effective tax rate of (64.8%).
Income tax benefit (provision) The income tax benefit in 2022 was $1,473 or an effective tax rate of (10.7%) as compared to a benefit in 2021 of $10,325 or an effective tax rate of (64.8%).
The discussion of results of operations that follows is based on revenue and expenses in total and for individual product lines and does not differentiate related party transactions. 34 Table of Contents Fiscal Year Ended December 31, 2022 Compared to Fiscal Year Ended December 31, 2021 Set forth below is a summary of certain financial information for the periods indicated.
The discussion of results of operations that follows is based on revenue and expenses in total and for individual product lines and does not differentiate related party transactions. 34 Table of Contents Fiscal Year Ended December 31, 2023 Compared to Fiscal Year Ended December 31, 2022 Set forth below is a summary of certain financial information for the periods indicated.
These hedging transactions are recognized in earnings and do not qualify as a hedge accounting treatment on our consolidated balance sheets at December 31, 2022 or 2021, as they do not meet the definition of a hedge instrument as defined under GAAP. The purchase of biofuels feedstock generally involves two components: basis and price.
These hedging transactions are recognized in earnings and do not qualify as a hedge accounting treatment on our consolidated balance sheets at December 31, 2023 or 2022, as they do not meet the definition of a hedge instrument as defined under GAAP. The purchase of biofuels feedstock generally involves two components: basis and price.
We are liable for these asset retirement obligations and environmental contingencies only in certain events, primarily the closure of our Batesville, Arkansas facility. As such, we do not expect a payment related to these liabilities in the foreseeable future and therefore we have excluded this amount from the table above. 45 Table of Contents
We are liable for these asset retirement obligations and environmental contingencies only in certain events, primarily the closure of our Batesville, Arkansas facility. As such, we do not expect a payment related to these liabilities in the foreseeable future and therefore we have excluded this amount from the table above. 44 Table of Contents
We will be permitted to use net proceeds of any borrowings under the Credit Facility for working capital and other general corporate purposes. No borrowings were made under the Credit Agreement or the Prior Credit Agreement as of December 31, 2022 and 2021. See Note 13 of the consolidated financial statements for additional information regarding our Credit Agreement.
We will be permitted to use net proceeds of any borrowings under the Credit Facility for working capital and other general corporate purposes. No borrowings were made under the Credit Agreement or the Prior Credit Agreement as of December 31, 2023 and 2022. See Note 13 of the consolidated financial statements for additional information regarding our Credit Agreement.
Bill-and-hold transactions for 2022 and 2021 were related to custom chemicals customers whereby revenue was recognized in accordance with contractual agreements based upon product being produced and ready for use by the customer. These sales were subject to written monthly purchase orders with agreement that production was reasonable.
Bill-and-hold transactions for 2023 and 2022 were related to custom chemicals customers whereby revenue was recognized in accordance with contractual agreements based upon product being produced and ready for use by the customer. These sales were subject to written monthly purchase orders with agreement that production was reasonable.
Liquidity and Capital Resources Our net cash provided by (used in) operating activities, investing activities, and financing activities for the years ended December 31, 2022, 2021, and 2020 are set forth in the following table.
Liquidity and Capital Resources Our net cash provided by (used in) operating activities, investing activities, and financing activities for the years ended December 31, 2023, 2022 and 2021 are set forth in the following table.
The Company’s effective tax rates for the years 2022 and 2021 reflect the positive effect of certain tax credits and incentives, the most significant of which are the BTC and the Small Agri-biodiesel Producer Tax Credit.
The Company’s effective tax rates for the years 2023 and 2022 reflect the positive effect of certain tax credits and incentives, the most significant of which are the BTC and the Small Agri-biodiesel Producer Tax Credit.
We have the capability to process multiple types of feedstocks including vegetable oils, animal fats, and separated food waste oils. We can receive feedstock by rail or truck, and we have substantial storage capacity to acquire feedstock at advantaged prices when market conditions permit. Our annual biodiesel production capacity is in excess of 58 million gallons per year.
We have the capability to process multiple types of feedstocks including vegetable oils, animal fats, and separated food waste oils. We can receive feedstock by rail or truck, and we have substantial storage capacity to acquire feedstock at advantaged prices when market conditions permit. Our annual biodiesel production capacity is 59 million gallons per year.
In years in which the Company has experienced objective negative evidence in the form of three cumulative years of tax losses, the Company no longer uses taxable income projections to overcome the presumption of losses and deferred tax asset valuations are computed taking into account tax planning strategies and the reversing net deferred tax liability as a source of income.
In years in which the Company has experienced objective negative evidence in the form of three cumulative years of tax losses, the Company no longer uses taxable income projections to overcome the presumption of losses and deferred tax asset valuations are computed taking into account tax planning strategies and the reversing net deferred tax liability from temporary differences as sources of income.
The Company’s effective tax rates for the years 2021 and 2020 reflect the positive effect of certain tax credits and incentives, the most significant of which are the BTC and the Small Agri-biodiesel Producer Tax Credit.
The Company’s effective tax rates for the years 2022 and 2021 reflect the positive effect of certain tax credits and incentives, the most significant of which was the BTC and the Small Agri-biodiesel Producer Tax Credit.
There currently is uncertainty as to whether we will produce biodiesel in the future. This uncertainty results from changes in feedstock prices relative to biodiesel prices and the lack of permanency of government mandates including the blenders’ tax credit, the small producer’s tax credit, the renewable fuels program, and the California low carbon fuel program credits.
There currently is uncertainty as to whether we will produce biodiesel in the future. This uncertainty results from changes in feedstock prices relative to biodiesel prices and the lack of permanency of government mandates including the BTC, the small producer’s tax credit, the CFPC (effective January 1, 2025), the renewable fuels program, and the California low carbon fuel program credits.
Dividends In 2022, we paid regular cash dividends aggregating $0.24 per share on our common stock with record dates and payment dates as previously discussed. The regular cash dividends totaled $10,503. In 2021, we paid regular cash dividends aggregating $0.24 per share on our common stock with record dates and payment dates as previously discussed.
In 2022, we paid regular cash dividends aggregating $0.24 per share on our common stock with record dates and payment dates as previously discussed. The regular cash dividends declared in 2022 totaled $21,006; $10,503 paid in 2022 and $10,503 paid in 2023.
The product was custom manufactured and stored at the customer’s request and could not be sold to another buyer. Credit and payment terms for bill-and-hold customers are similar to other custom chemicals customers. Sales revenue under bill-and-hold arrangements were $36,805, $34,655, and $32,779 for the years ended December 31, 2022, 2021, and 2020, respectively.
The product was custom manufactured and stored at the customer’s request and could not be sold to another buyer. Credit and payment terms for bill-and-hold customers are similar to other custom chemicals customers. Sales revenue under bill-and-hold arrangements were $43,766, $36,805, and $34,695 for the years ended December 31, 2023, 2022 and 2021, respectively.
At December 31, 2022 and 2021, $4,473 and $3,154, respectively, was included in revenue for products that had not shipped. The latter amounts do not include Contract Assets of $775 and $362 that have not been billed nor shipped at December 31, 2022 and 2021, respectively.
At December 31, 2023 and 2022, $4,317 and $4,473, respectively, was included in revenue for products that had not shipped. The latter amounts do not include Contract Assets of $734 and $775 that have not been billed nor shipped at December 31, 2023 and 2022, respectively.
The fair value of these preferred stock, trust preferred securities, and other equity instruments, including accrued dividends and interest, totaled $37,126 and $47,190 as of December 31, 2022 and 2021, respectively. The unrealized losses on equity securities were $8,297 and $904 for December 31, 2022 and 2021, respectively.
The fair value of these preferred stock, trust preferred securities, and other equity instruments, including accrued dividends and interest, totaled $0 and $37,126 as of December 31, 2023 and 2022, respectively. The unrealized losses on equity securities were $0 and $8,297 as of December 31, 2023 and 2022, respectively.
Major products in the custom chemicals group include: (i) consumer products (cosmetics and personal care products, specialty polymers, and specialty products used in the fuels industry) ; (ii) chlorinated polyolefin adhesion promoters and antioxidant precursors for a customer; and (iii) a biocide intermediate for another customer.
Major products in the custom chemicals group include: (i) consumer products (cosmetics and personal care products, specialty polymers, and specialty products used in the fuels industry); (ii) chlorinated polyolefin adhesion promoters and antioxidant precursors for a customer; and (iii) a biocide intermediate. Pricing for the other custom manufacturing products is negotiated directly with the customer.
We include this item as an adjustment as we believe it provides a relevant indicator of the underlying performance of our business in a given period. 35 Table of Contents The following table reconciles adjusted EBITDA with net income, the most directly comparable GAAP financial measure.
We include the unrealized gains and losses on the derivative instruments as an adjustment as we believe it provides a relevant indicator of the underlying performance of our business in a given period. 35 Table of Contents The following table reconciles adjusted EBITDA with net income, the most directly comparable GAAP financial measure.
In 2020, we paid regular cash dividends aggregating $0.24 per share on our common stock with record dates and payment dates as previously discussed. The regular cash dividends totaled $10,498. On March 23, 2020, we also declared a special cash dividend of $3.00 per share on our common stock.
In 2021, we paid regular cash dividends aggregating $0.24 per share on our common stock with record dates and payment dates as previously discussed. The regular cash dividends totaled $10,498. On May 10, 2021, we also declared a special cash dividend of $2.50 per share on our common stock.
All Foreign Period United States Countries Total Year ended December 31, 2022 $ 394,671 $ 1,343 $ 396,014 Year ended December 31, 2021 $ 320,148 $ 1,238 $ 321,386 Year ended December 31, 2020 $ 203,365 $ 1,140 $ 204,505 The majority of our expenses are cost of goods sold.
All Foreign Period United States Countries Total Year ended December 31, 2023 $ 367,368 $ 882 $ 368,250 Year ended December 31, 2022 $ 394,671 $ 1,343 $ 396,014 Year ended December 31, 2021 $ 320,148 $ 1,238 $ 321,386 The majority of our expenses are cost of goods sold.
Contractual Obligations Purchase obligations include the purchase of biodiesel feedstock and various other infrastructure and capital repairs as follows: Less than 1 year $ 59,111 1-3 years 785 4-5 years 177 More than 5 years - Total $ 60,073 A component of other noncurrent liabilities is a reserve for asset retirement obligations and environmental contingencies of $1,396 at December 31, 2022.
Contractual Obligations Purchase obligations include the purchase of biodiesel feedstock and various other infrastructure and capital repairs as follows: Less than 1 year $ 45,389 1-3 years 43 4-5 years - More than 5 years - Total $ 45,432 A component of other noncurrent liabilities is a reserve for asset retirement obligations and environmental contingencies of $1,431 at December 31, 2023.
Partially improving gross profit was (i) the change in adjustments in the carrying value of our inventory as determined utilizing the last-in, first-out (“LIFO”) method of inventory accounting reduced gross profit $9,921 in 2021 as compared to $5,794 in 2022, (ii) the liquidation effect of exiting the pipeline business, which increased profits $1,851 in 2022, and (iii) 2021 gross profit was unfavorably impacted by higher natural gas prices incurred from Winter Storm Uri. 2021 Compared to 2020 Biofuels sales revenue increased 102.5% or $128,517 in 2021 compared to 2020, primarily from increased selling prices of biodiesel and biodiesel blends, inclusive of separated RIN sales.
Partially improving gross profit was (i) the change in adjustments in the carrying value of our inventory as determined utilizing the LIFO method of inventory accounting reduced gross profit $9,921 in 2021 as compared to $5,794 in 2022, (ii) the liquidation effect of exiting the pipeline business, which increased profits $1,851 in 2022, and (iii) 2021 gross profit was unfavorably impacted by higher natural gas prices incurred from Winter Storm Uri.
The Company’s unrecognized tax benefit totaled $0 at December 31, 2021 and 2020. 38 Table of Contents Chemicals Segment 2022 Compared to 2021: 2021 Compared to 2020: Change Change (Dollars in thousands) 2022 2021 $ % 2021 2020 $ % Sales $ 80,893 $ 67,542 $ 13,351 19.8 % $ 67,542 $ 79,178 $ (11,636 ) (14.7 %) Volume/product mix effect (1,137 ) (1.7 )% (14,285 ) (18.0 %) Price effect 14,488 21.5 % 2,649 3.3 % Gross profit $ 25,645 $ 13,970 $ 11,675 83.6 % $ 13,970 $ 25,518 $ (11,548 ) (45.3 %) 2022 Compared to 2021 Chemical sales revenue increased 19.8% or $13,351 in 2022 compared with 2021.
The Company’s unrecognized tax benefit totaled $0 at December 31, 2022 and 2021. 38 Table of Contents Chemicals Segment 2023 Compared to 2022: 2022 Compared to 2021: Change Change (Dollars in thousands) 2023 2022 $% 2022 2021 $% Sales $ 79,333 $ 80,893 $ (1,560 ) (1.9 )% $ 80,893 $ 67,542 $ 13,351 19.8 % Volume/product mix effect 356 0.4 % (1,137 ) (1.7 )% Price effect (1,916 ) (2.4 )% 14,488 21.5 % Gross profit $ 29,936 $ 25,645 $ 4,291 16.7 % $ 25,645 $ 13,970 $ 11,675 83.6 % 2023 Compared to 2022 Chemical sales revenue decreased 1.9% or $1,560 in 2023 compared with 2022.
While many of our chemicals are used to manufacture products that are shipped, further processed, and/or consumed throughout the world, the chemical products, with limited exceptions, generally leave the United States only after we have transferred ownership.
Most of our sales are FOB the Batesville plant, although some transfer points are in other states or foreign ports. While many of our chemicals are used to manufacture products that are shipped, further processed, and/or consumed throughout the world, the chemical products, with limited exceptions, generally leave the United States only after we have transferred ownership.
We also hold certain trust preferred securities. We classify these investments as current assets in the accompanying consolidated balance sheets and designate them as being “available-for-sale”. Accordingly, they are recorded at fair value with the unrealized gains and losses, net of taxes, reported as a component of stockholders’ equity.
We classified these investments as current assets in the accompanying consolidated balance sheets and designate them as being “available-for-sale”. Accordingly, they were recorded at fair value with the unrealized gains and losses, net of taxes, reported as a component of stockholders’ equity. We exited our position in these marketable securities during 2023.
This activity was captured on our consolidated balance sheets at December 31, 2022 and 2021. Second, we hedge our biofuels feedstock through the execution of purchase contracts and supply agreements with certain vendors which meet the normal purchase and normal sales exception of ASC 815 Derivatives and Hedging .
Second, we hedge our biofuels feedstock through the execution of purchase contracts and supply agreements with certain vendors which meet the normal purchase and normal sales exception of ASC 815 Derivatives and Hedging .
Increased capital expenditures decreased cash from investing activities by $3,322. Cash provided by investing activities was $14,993 in 2021 compared to $474 in 2020 for a net increase in cash from investing activities of $14,519.
Increased capital expenditures decreased cash from investing activities by $1,244. Cash used by investing activities was $3,829 in 2022 compared to cash provided by investing activities of $14,993 in 2021 for a net decrease in cash of $18,822.
Other expense increased $6,840 from 2022 primarily from realized and unrealized losses on equity securities with a loss of $8,546 in 2022 as compared to a loss of $70 in 2021 (see Note 7 of our consolidated financial statements for further details).
This increase was primarily the result of increased compensation expense. Other expense increased $6,840 from 2022 primarily from realized and unrealized losses on equity securities with a loss of $8,546 in 2022 as compared to a loss of $70 in 2021.
Adjusted EBITDA has limitations as an analytical tool and should not be considered in isolation or as a substitute for analysis of results as reported under GAAP.
Adjusted EBITDA is not a substitute for operating income, net income, or cash flow from operating activities (each as determined in accordance with GAAP) as a measure of performance or liquidity. Adjusted EBITDA has limitations as an analytical tool and should not be considered in isolation or as a substitute for analysis of results as reported under GAAP.
Investing Activities Cash used by investing activities was $3,829 in 2022 compared to cash provided by investing activities of $14,993 in 2021 for a net decrease in cash of $18,822. This decrease was primarily attributable to sales of marketable securities in 2022 of $1,292 compared to the net sales of marketable securities in 2021 of $17,106.
Investing Activities Cash provided by investing activities was $30,336 in 2023 compared to cash used by investing activities of $3,829 in 2022 for a net increase in cash of $34,165. This increase was primarily attributable to the sale of marketable securities in 2023 of $37,701 compared to sales of marketable securities in 2022 of $1,292.
(Dollars in thousands) 2022 2021 2020 Net cash provided by operating activities $ 52,451 $ 44,084 $ 96,403 Net cash (used) provided by investing activities $ (3,829 ) $ 14,993 $ 474 Net cash used in financing activities $ (10,503 ) $ (119,678 ) $ (142,086 ) 42 Table of Contents Operating Activities Cash provided by operating activities increased in 2022 to $52,451 from $44,084 in 2021, a net increase of $8,367.
(Dollars in thousands) 2023 2022 2021 Net cash provided by operating activities $ 23,985 $ 52,451 $ 44,084 Net cash provided by (used in) investing activities $ 30,336 $ (3,829 ) $ 14,993 Net cash used in financing activities $ (10,517 ) $ (10,503 ) $ (119,678 ) 41 Table of Contents Operating Activities Cash provided by operating activities decreased in 2023 to $23,985 from $52,451 in 2022, a net decrease of $28,466.
Financing Activities Cash used in financing activities decreased to $10,503 in 2022, from $119,678 in 2021, a net increase of $109,175. This increase resulted from the payment of special cash dividends in 2021 of $109,408 compared to $0 in 2022. Cash used in financing activities decreased from $142,086 in 2020 to $119,678 in 2021, a net decrease of $22,408.
Cash used in financing activities decreased to $10,503 in 2022, from $119,678 in 2021, a net decrease of $109,175. This decrease resulted from the payment of special cash dividends in 2021 of $109,408 compared to $0 in 2022. Capital Expenditure Commitments We had $560 of infrastructure capital repair projects that generated commitments as of December 31, 2023.
The Company’s unrecognized tax benefit totaled $0 at December 31, 2022 and 2021. 37 Table of Contents 2021 Compared to 2020 Consolidated sales revenue increased 57.2% or $116,881 in 2021 compared to 2020. This increase primarily resulted from higher average sales prices in the biofuel segment reduced in part by lower sales volumes in both the biofuels and chemicals segment.
The Company’s unrecognized tax benefit totaled $0 at December 31, 2023 and 2022. 37 Table of Contents 2022 Compared to 2021 Consolidated sales revenue increased 23.2% or $74,628 in 2022 compared to 2021 primarily from higher average sales prices in the biofuel segment and, to a lesser extent, in the chemical segment.
The Company’s effective tax rate for 2022 includes an expense of $7,392 or 53.8% from the recording of a valuation allowance against its deferred tax assets. The Company evaluates its deferred tax assets and records a valuation allowance to reduce these assets to the amount that is more likely than not to be realized.
The Company evaluates its deferred tax assets and records a valuation allowance to reduce these assets to the amount that is more likely than not to be realized.
Partially offsetting this improvement in gross profit was the unfavorable change in the realized and unrealized activity of derivative instruments which resulted in a reduction in gross profit of $24,360 in 2022, as compared to a reduction in gross profit in 2021 by $10,377.
Partially offsetting this improvement in gross profit was the unfavorable change in the realized and unrealized activity of derivative instruments which resulted in a reduction in gross profit of $10,500 in 2022. The comparative unfavorable change was primarily from the unprecedented volatility in the NYMEX heating oil futures market. Operating expenses increased $808 in 2022 compared to 2021.
Performance chemicals revenue (comprised of multi-customer products which are sold based on specification) was $16,867 in 2021, an increase of 10.4% or $1,583 from 2020. This increase resulted from higher selling prices of our glycerin products. Gross profit for the chemicals segment decreased 45.3% or $11,548 in 2021 compared with 2020.
Performance chemicals revenue (comprised of multi-customer products which are sold based on specification) was $15,047 in 2023, a decrease of 32.1% or $7,109 from 2022. This decrease resulted from lower selling prices of our glycerin products partially offset by higher volumes. Gross profit for the chemicals segment increased 16.7% or $4,291 in 2023 compared with 2022.
Lastly, we maintain depository accounts such as checking accounts, money market accounts, and other similar accounts at selected financial institutions. Off-Balance Sheet Arrangements We engage in two types of hedging transactions. First, we hedge our biofuels sales through the purchase and sale of futures contracts and options on futures contracts of energy commodities.
Lastly, we maintain depository accounts such as checking accounts, money market accounts, and other similar accounts at selected financial institutions. As of December 31, 2023, approximately 55% of these deposits were insured by the Federal Deposit Insurance Corporation. Off-Balance Sheet Arrangements We engage in two types of hedging transactions.
In addition, we deliver blended product to a small group of customers within our region. We also sell D4 RINs from time to time. At December 31, 2022, we had 1.5 million D4 RINs in inventory. Most of our sales are FOB the Batesville plant, although some transfer points are in other states or foreign ports.
In addition, we deliver blended product to a small group of customers within our region. We also sell D4 and D6 RINs from time to time. At December 31, 2023 we held 4.3 million RINs with a market value of $6,567 and at December 31, 2022, we held 1.5 million RINs in inventory with a market value of $2,557.
This decrease resulted primarily from: (i) the loss of two custom chemical products we no longer sell; (ii) the impact of higher natural gas prices incurred during Winter Storm Uri in February 2021; and (iii) increased material cost driven by inflation and the supply chain disruption caused by the COVID-19 pandemic and the responses to it. 39 Table of Contents Biofuel Segment 2022 Compared to 2021: 2021 Compared to 2020: Change Change (Dollars in thousands) 2022 2021 $ % 2021 2020 $ % Sales $ 315,121 $ 253,844 $ 61,277 24.1 % $ 253,844 $ 125,327 $ 128,517 102.5 % Volume/product mix effect (29,164 ) (11.5 %) (7,003 ) (5.6 %) Price effect 90,441 35.6 % 135,520 108.1 % Gross profit $ 3,348 $ 9,567 $ (6,219 ) (65.0 %) $ 9,567 $ 5,789 $ 3,778 65.3 % 2022 Compared to 2021 Biofuels sales revenue increased 24.1% or $61,277 in 2022 compared to 2021, primarily from increased selling prices of biodiesel and biodiesel blends, inclusive of separated RIN sales.
In addition, the prior year gross profit was negatively impacted from higher natural gas prices incurred from Winter Storm Uri. 39 Table of Contents Biofuel Segment 2023 Compared to 2022: 2022 Compared to 2021: Change Change (Dollars in thousands) 2023 2022 $% 2022 2021 $% Sales $ 288,917 $ 315,121 $ (26,204 ) (8.3 )% $ 315,121 $ 253,844 $ 61,277 24.1 % Volume/product mix effect 44,994 14.3 % (29,164 ) (11.5 )% Price effect (71,198 ) (22.6 )% 90,441 35.6 % Gross profit $ 11,043 $ 3,348 $ 7,695 229.8 % $ 3,348 $ 9,567 $ (6,219 ) (65.0 )% 2023 Compared to 2022 Biofuels sales revenue decreased 8.3% or $26,204 in 2023 compared to 2022, primarily from decreased selling prices of biodiesel and biodiesel blends, inclusive of a decline in separated RIN sale prices.
Third parties have not placed significant restrictions on our working capital management decisions. A significant portion of these funds were held in cash or cash equivalents at multiple financial institutions. In 2022 and 2021, we also had investments in certain preferred stock and other equity instruments measured at fair value and changes in fair value recognized in net income.
We intend to retain the remaining cash to fund infrastructure and capacity expansion at our Batesville plant or to otherwise fund our future growth. Third parties have not placed significant restrictions on our working capital management decisions. A significant portion of these funds were held in cash or cash equivalents at multiple financial institutions.
This increase was primarily attributable to a $12,376 increase in the net sales of marketable securities in 2021 compared to the net sales of marketable securities in 2020. Such net sales totaled $17,106 in 2021, as compared to total net sales of $4,730 in 2020. Reduced capital expenditures increased cash from investing activities by $3,008.
This decrease was primarily attributable to sales of marketable securities in 2022 of $1,292 compared to the net sales of marketable securities in 2021 of $17,106. Increased capital expenditures decreased cash from investing activities by $3,322. Financing Activities Cash used in financing activities was $10,517 in 2023, primarily from the payment of dividends of $10,503.
Based on technical guidance from the Internal Revenue Service, the Company excludes the portion of the BTC not used to satisfy excise tax liabilities from income. See Note 3 for a discussion of the pretax earnings impact of the BTC.
Based on technical guidance from the Internal Revenue Service, the Company excludes the portion of the BTC not used to satisfy excise tax liabilities from income. The Company’s effective tax rate for 2022 includes an expense of $7,392 or 53.8% from the recording of a valuation allowance against its deferred tax assets.
Partially reducing gross profit in 2021 was the change in the realized and unrealized activity of derivative instruments in comparison to the prior year with a loss of $10,377 as compared to a gain of $4,379 in 2020. 40 Table of Contents Critical Accounting Policies and Estimates Useful Lives of Property, Plant, and Equipment We primarily base our estimate of an asset’s useful life on our experience with other similar assets.
Critical Accounting Policies and Estimates Useful Lives of Property, Plant, and Equipment We primarily base our estimate of an asset’s useful life on our experience with other similar assets.
The regular cash dividends totaled $10,498. On May 10, 2021, we also declared a special cash dividend of $2.50 per share on our common stock. This special cash dividend paid on June 4, 2021, amounted to $109,408. Total cash dividends paid in 2021 were $119,906.
This special cash dividend paid on June 4, 2021, amounted to $109,408. Total cash dividends paid in 2021 were $119,906. 43 Table of Contents Capital Management As a result of positive operating results, we accumulated excess working capital.
This increase resulted primarily from stronger margins and higher sales volumes in products sold into the oil and gas industry and glycerin markets. In addition, the prior year gross profit was negatively impacted from higher natural gas prices incurred from Winter Storm Uri. 2021 Compared to 2020 Chemical sales revenue decreased 14.7% or $11,636 in 2021 compared with 2020.
This increase resulted primarily from stronger margins and higher sales volumes in products sold into the oil and gas industry and glycerin markets.
This special cash dividend paid on April 17, 2020, amounted to $131,230. Total cash dividends paid in 2020 were $141,728. On December 3, 2020, we declared normal quarterly dividends of $0.06 per share on our common stock with record dates and payment dates as previously discussed.
Dividends In 2023, we paid regular cash dividends aggregating $0.24 per share on our common stock with record dates and payment dates as previously discussed. The regular cash dividends declared in 2023 totaled $10,503 to be paid in 2024.
Partially improving other income was the absence of realized and unrealized losses on equity securities in 2021 as compared to 2020 (see Note 7 of our consolidated financial statements).
As a result, interest and dividend income increased $4,707 in 2023 as compared to 2022. The net realized gain on the sale of marketable securities was $575 in 2023 as compared to an unrealized loss of $8,546 in 2022 (see Note 7 of our consolidated financial statements for further details).
Cash provided by operating activities decreased in 2021 to $44,084 from $96,403 in 2020, a net decrease of $52,319. This decrease was attributed to the change in accounts receivable, including accounts receivable - related parties, of $98,602. The BTC increased cash from accounts receivable in 2020 by $97,295. Additionally, net income decreased in 2021 compared to 2020 by $20,309.
Partially offsetting the decrease in cash from operations was the increase of $22,137 in net income in 2023 compared to 2022. Cash provided by operating activities increased in 2022 to $52,451 from $44,084 in 2021, a net increase of $8,367.